Eli Lilly and Company - Asset Resilience Ratio
Eli Lilly and Company (LLY) has an Asset Resilience Ratio of 0.13% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LLY current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Eli Lilly and Company's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Eli Lilly and Company total assets.
Liquid Assets Composition Over Time
This chart breaks down Eli Lilly and Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Eli Lilly and Company (LLY) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $146.00 Million | 0.13% |
| Total Liquid Assets | $146.00 Million | 0.13% |
Asset Resilience Insights
- Limited Liquidity: Eli Lilly and Company maintains only 0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Eli Lilly and Company Industry Peers by Asset Resilience Ratio
Compare Eli Lilly and Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
Annual Asset Resilience Ratio for Eli Lilly and Company (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Eli Lilly and Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.56% | $7.37 Billion | $112.48 Billion | +2.21pp |
| 2024-12-31 | 4.35% | $3.42 Billion | $78.71 Billion | -0.23pp |
| 2023-12-31 | 4.57% | $2.93 Billion | $64.01 Billion | +0.10pp |
| 2022-12-31 | 4.47% | $2.21 Billion | $49.49 Billion | -3.54pp |
| 2021-12-31 | 8.01% | $3.91 Billion | $48.81 Billion | +0.11pp |
| 2020-12-31 | 7.89% | $3.68 Billion | $46.63 Billion | +1.69pp |
| 2019-12-31 | 6.21% | $2.44 Billion | $39.29 Billion | -10.67pp |
| 2018-12-31 | 16.87% | $7.41 Billion | $43.91 Billion | -0.99pp |
| 2017-12-31 | 17.86% | $8.03 Billion | $44.98 Billion | +2.30pp |
| 2016-12-31 | 15.56% | $6.04 Billion | $38.81 Billion | +13.35pp |
| 2015-12-31 | 2.21% | $785.40 Million | $35.57 Billion | -0.42pp |
| 2014-12-31 | 2.63% | $955.40 Million | $36.31 Billion | -1.81pp |
| 2013-12-31 | 4.45% | $1.57 Billion | $35.25 Billion | -0.40pp |
| 2012-12-31 | 4.84% | $1.67 Billion | $34.40 Billion | +1.95pp |
| 2011-12-31 | 2.90% | $974.60 Million | $33.66 Billion | +0.53pp |
| 2010-12-31 | 2.37% | $733.80 Million | $31.00 Billion | +2.24pp |
| 2009-12-31 | 0.13% | $34.70 Million | $27.46 Billion | -1.34pp |
| 2008-12-31 | 1.47% | $429.40 Million | $29.21 Billion | -4.54pp |
| 2007-12-31 | 6.01% | $1.61 Billion | $26.79 Billion | +2.45pp |
| 2006-12-31 | 3.56% | $781.70 Million | $21.96 Billion | -4.70pp |
| 2005-12-31 | 8.26% | $2.03 Billion | $24.58 Billion | -0.18pp |
| 2004-12-31 | 8.44% | $2.10 Billion | $24.87 Billion | +4.03pp |
| 2003-12-31 | 4.41% | $957.00 Million | $21.68 Billion | -4.56pp |
| 2002-12-31 | 8.97% | $1.71 Billion | $19.04 Billion | +2.71pp |
| 2001-12-31 | 6.26% | $1.03 Billion | $16.43 Billion | +2.83pp |
| 2000-12-31 | 3.43% | $503.30 Million | $14.69 Billion | +2.37pp |
| 1999-12-31 | 1.06% | $135.60 Million | $12.83 Billion | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more